Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters
Cholesteryl ester transfer protein (CETP) transfers cholesteryl ester (CE) and triglyceride between HDL and apoB-containing lipoproteins. Anacetrapib (ANA), a reversible inhibitor of CETP, raises HDL cholesterol (HDL-C) and lowers LDL cholesterol in dyslipidemic patients; however, the effects of ANA...
Main Authors: | Jose Castro-Perez, François Briand, Karen Gagen, Sheng-Ping Wang, Ying Chen, David G. McLaren, Vinit Shah, Rob J. Vreeken, Thomas Hankemeier, Thierry Sulpice, Thomas P. Roddy, Brian K. Hubbard, Douglas G. Johns |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2011-11-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520350860 |
Similar Items
-
In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption
by: Sheng-Ping Wang, et al.
Published: (2013-10-01) -
Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9[S]
by: Sam J.L. van der Tuin, et al.
Published: (2015-11-01) -
Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia
by: Alexina Orsoni, et al.
Published: (2012-04-01) -
Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys
by: Mathieu R. Brodeur, et al.
Published: (2017-07-01) -
Scavenger receptor class B type I-mediated uptake of serum cholesterol is essential for optimal adrenal glucocorticoid production
by: Menno Hoekstra, et al.
Published: (2009-06-01)